April – June Revenues amounted to MSEK 747.9 (688.9), corresponding to an increase of +9% for the period. The organic growth1 during the second quarter was +8%. The currency impact in the quarter was 0% while the acquisitions of the product portfolios Pevaryl® from Johnson & Johnson and Flux®, Decubal®, Apobase®, Lactocare® from Teva generated...
Karo Pharma AB (“Karo”) today announces the divestment of a portfolio consisting of 12 brands to Evolan Pharma AB (“Evolan”). The transaction is effective per today, July 1[st], 2021.
Karo Pharma (“Karo”) pursues a growth strategy, which combines geographical expansion with an active acquisition strategy. To execute on this strategy, Karo needs capital and a strong financial position. The treasury shares represent an unutilized resource in the company and a sale of the shares enhances Karo’s financial flexibility. On October 30, 2020 Karo communicated...
Under the the authorization from the 2021 Annual General Meeting, the Board of Directors has resolved to sell up to 1,768,000 own shares to expand the company’s financial flexibility. The sale of own shares shall be effected – on one or several occasions before the 2022 Annual General Meeting, where a new mandate should be...
January – March Revenues amounted to MSEK 713.0 (793.6), corresponding to a decrease of -10% for the period. The organic growth* during the first quarter was -16%. The currency impact in the quarter was -1% while the acquisitions of the product portfolios Proct® from Leo Pharma and Pevaryl® from Johnson & Johnson generated growth of...
Karo Pharma Aktiebolag (“Karo”) today announces that the acquisition of the European OTC brand portfolio from Teva Pharmaceuticals (Teva) for 84 MEUR, which was signed and announced on 3 February 2021, has been completed. The transaction transfers ownership of the brand portfolio, comprised of Flux ®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva to...
Today, on 30 March 2021, Karo Pharma is publishing its annual report for 2020 on the company’s website, www.karopharma.com. For further information, please contact: Jon Johnsson, CFO, 073-507 88 61, jon.johnsson@karopharma.com The Annual Report is published in Swedish and English. The Swedish version represents the original version and has been translated into English. This information...
Q4, October – December Net sales amounted to MSEK 721.2 (649.3). This corresponds to an increase of 11% for the period. The organic growth* during the fourth quarter was +1%. The currency impact in the quarter was -1% while the acquisitions of the product portfolios Proct® from Leo Pharma and Pevaryl® from Johnson & Johnson...
Karo Pharma Aktiebolag (“Karo”) today announces the acquisition of an OTC brand portfolio containing Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva Pharmaceuticals (Teva) for a total consideration of EUR 84m.
